Gliriv-M2 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, resulting in enhanced glucose uptake by muscle tissues. The combination of these agents provides complementary mechanisms to achieve better glycemic control in patients inadequately managed by diet and exercise alone. Gliriv-M2 Tablet PR is formulated as a prolonged-release tablet to ensure sustained plasma concentrations, improving patient compliance and minimizing gastrointestinal side effects commonly associated with metformin. It is recommended to be administered once daily with meals to optimize absorption and reduce adverse effects. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential hypoglycemic episodes is essential during therapy. Gliriv-M2 Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and weight control to achieve optimal therapeutic outcomes.